ACADIA PharmaceuticalsMEX:ACAD 73 Net Current Asset Value is MXN77.88 as of Mar. 2026, which is 100% below its 10-year median of 8.39. GuruFocus rates MEX:ACAD with a GF Score™ of 73/100 and a GF Value™ of MXN350.43 (Fairly Valued). The stock has 10 warning signs investors should review. Among 946 Biotechnology companies, ACADIA Pharmaceuticals ranks worse than 58.35% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
ACADIA Pharmaceuticals's net current asset value per share for the quarter that ended in Mar. 2026 was MXN77.88.
The historical rank and industry rank for ACADIA Pharmaceuticals's Net Current Asset Value or its related term are showing as below:
MEX:ACAD'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.01 Med: 8.39 Max: 17.2
Current: 6.01
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of ACADIA Pharmaceuticals was 17.20. The lowest was 5.01. And the median was 8.39.
MEX:ACAD's Price-to-Net-Current-Asset-Value is ranked worse than 58.35% of 946
companies
in the Biotechnology industry
Industry Median: 4.955
vs MEX:ACAD: 6.01
ACADIA Pharmaceuticals (MEX:ACAD) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
ACADIA Pharmaceuticals Net Current Asset Value Related Terms
ACADIA Pharmaceuticals Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for ACADIA Pharmaceuticals's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals Net Current Asset Value Chart
MEX:ACAD vs VKTX, EWTX, DNLI: Net Current Asset Value Comparison
For the Biotechnology subindustry, ACADIA Pharmaceuticals's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of MXN77.88 mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Net Current Asset Value of MXN77.88 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on ACADIA Pharmaceuticals and its competitors. This is 828% above median its historical median of 8.39. Over the past decade, ACADIA Pharmaceuticals' Net Current Asset Value has ranged from 5.01 to 17.20. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #552 out of 946 companies in the Biotechnology industry, placing it in the top 58.4%.
Is ACADIA Pharmaceuticals' Net Current Asset Value too high?
ACADIA Pharmaceuticals' current Net Current Asset Value of MXN77.88 is 828% above median its 10-year median of 8.39. Over the past 10 years, this metric has ranged from a low of 5.01 to a high of 17.20. Based on the distribution chart, ACADIA Pharmaceuticals ranks #552 out of 946 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Net Current Asset Value compare to VKTX and EWTX?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #552 out of 946 companies for Net Current Asset Value. This places ACADIA Pharmaceuticals in the lower half of its industry. The industry median Net Current Asset Value is 4.96. Historically, ACADIA Pharmaceuticals' own Net Current Asset Value has ranged from 5.01 to 17.20 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.96, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on ACADIA Pharmaceuticals and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACADIA Pharmaceuticals's current Net Current Asset Value is MXN77.88, which is 828% above median its own 10-year median of 8.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN350.43, compared to a current price of MXN362.00 — trading 3.3% above its estimated fair value. The current Net Current Asset Value is MXN77.88, which is 828% above median its 10-year median of 8.39. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Net Current Asset Value is MXN77.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN362.00 is trading 3.3% above its estimated GF Value™ of MXN350.43.
GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:ACAD:
Net Current Asset Value: MXN77.88 (828% above median its 10-year median of 8.39)
GF Value™: MXN350.43 vs. price of MXN362.00 (3.3% above fair value)
No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score
Get the complete analysis for MEX:ACAD
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ACAD has been successfully added to your 
